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ABSTRACT 
Background: One of the goals of cancer treatment is symptoms management especially at the 
end stage. The common symptoms in cancer include pain, fatigue, depression and cognitive 
dysfunction. The available treatment options for symptom management are limited. 
Methylphenidate, a psychostimulant, may be of benefit for these patients. In this report, we 
review the use of methylphenidate for symptoms control in cancer patients. Method: 
Electronic literature search on PubMed was conducted using the following keywords: 
methylphenidate, cancer, carcinoma, oncology, oncological and tumour. We identified forty 
two relevant studies and publications on the use of methylphenidate in cancer patients to be 
included in this review. Results: Methylphenidate was found to have some evidence in 
reducing opioid-induced sedation, improving cognitive symptoms and reduction of fatigue in 
cancer patients. Nevertheless, the results were inconsistent due to variations in the study 
populations, study design and outcome measures, among others. There was minimal evidence 
on its use in treating depression. Otherwise, methylphenidate was generally well-tolerated by 
patients. Conclusion: This review potentially supports the use of methylphenidate for opioid-
induced sedation, cognitive decline and fatigue in cancer patients. Further placebo-controlled 
trials would help in strengthening the evidence for this treatment. 
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